Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study

objectives: to evaluate, in a multicentric italian cohort of axial spondyloarthritis (axSpA) patients on secukinumab (SEC) followed for 24 months: (1) the long-term effectiveness and safety of SEC; (2) the drug retention rate and low disease activity (LDA) measured as bath ankylosing spondylitis disease activity Index (BASDAI) < 4/ankylosing spondylitis disease activity score (ASDAS) < 2.1 and very low disease activity (VLDA) measured as BASDAI <2/ ASDAS < 1.3; (3) any differences in outcomes according to line of biological treatment (naive/ non-naive), gender (male/female), subtype of axSpA [radiographic axSpA (r-axSpA)/nonradiographic axSpA (nr-axSpA)].methods: consecutive axSpA patients treated with SEC were evaluated prospectively. disease characteristics, previous/ongoing treatments, comorbidities, and follow-up duration were collected. disease activity/functional/clinimetric scores and biochemical-values were recorded at baseline (T0), 6 (T6), 12 (T12), and 24 (T24) months. Effectiveness was evaluated over-time with descriptive statistics; multivariate Cox and logistic regression models were used to evaluate predictors of drug discontinuation and LDA at T6. Infections and adverse events were recorded.Results: A total 249 patients (47.8% male; median age 51) were enrolled; 40.9% had HLA-B27; 53.8% had r-axSpA, and 46.2% nr-axSpA. SEC was prescribed in 28.9% naive and in 71.1% non-naive patients. SEC effectiveness was shown as an improvement in several outcomes, such as ASDAS [T0=3.5 (2.9-4.4) versus T24=1.9 (1.2-2.4); p =0.02] and BASDAI [T0=6.5 (5.0-7.5) versus T24=2.8 (1.8-4.0); p = 0.03]. At T24, naive patients showed better physical functioning and lower disease activity than non-naive. After 24 months of treatment, 90.7% of naive and 75.3% of non-naive patients achieved LDA (BASDAI < 4). treatment was discontinued in 24.5% patients, mainly due to primary/secondary loss of effectiveness, and in 6.8% due to adverse events. retention rate at T24 was 75% in the whole population, with some difference depending on gender (p=0.002).conclusion: In a real-life clinical setting, SEC proved to be safe and effective in axSpA, mainly in naive-patients, with a notable drug retention rate. no differences were observed between r-axSpA and nr-axSpA